Am J Perinatol 2015; 32(02): 137-142
DOI: 10.1055/s-0034-1376390
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Effects of Saccharomyces boulardii on Neonatal Hyperbilirubinemia: A Randomized Controlled Trial

Ozge Serce
1  Neonatology Unit, Zeynep Kamil Maternity and Children's Research and Training Hospital, Istanbul, Turkey
,
Tugba Gursoy
1  Neonatology Unit, Zeynep Kamil Maternity and Children's Research and Training Hospital, Istanbul, Turkey
,
Fahri Ovali
1  Neonatology Unit, Zeynep Kamil Maternity and Children's Research and Training Hospital, Istanbul, Turkey
,
Guner Karatekin
1  Neonatology Unit, Zeynep Kamil Maternity and Children's Research and Training Hospital, Istanbul, Turkey
› Author Affiliations
Further Information

Publication History

06 February 2014

03 April 2014

Publication Date:
10 June 2014 (online)

Abstract

Objective Since probiotics modulate intestinal functions and enterohepatic circulation; they might have an effect on neonatal hyperbilirubinemia treatment. The objective of this study was to investigate the efficacy of Saccharomyces boulardii supplementation on hyperbilirubinemia.

Study Design A prospective, double-blind, placebo controlled trial was performed on 35 to 42 gestational weeks' neonates. They were randomized either to receive feeding supplementation with S. boulardii 125 mg every 12 hours or placebo during phototherapy. Serum bilirubin levels were measured at 0, 24th, 48th, 72nd, and 96th hour of phototherapy.

Results A total of 119 infants (61 in the control group and 58 in the study group) were enrolled. The duration of phototherapy (2 [1–3] vs. 2 [1–3], p: 0.22) was not different between groups. The levels of bilirubin during phototherapy ([24th hour; 14.1 {12.8–15.7} vs. 13.5 {12.4–14.9}, p: 0.085]; [48th hour; 14.1 {12–15.3} vs. 13.4 {12.4–14.5}, p: 0.41]; [72nd hour; 13.9 {12.2–15.6} vs. 13.5 {12.5–14.5}, p: 0.41]; [96th hour; 14.7 {11.4–15.5} vs. 13.4 {10.7–14.1}, p: 0.24]) or the duration of rebound phototherapy (1 [1–1] vs. 1.5 [1–2], p: 0.40) were lower in the study group than in the controls, but none of the values were statistically significant.

ConclusionS. boulardii did not influence the clinical course of hyperbilirubinemia significantly.

Note

The full trial protocol can be accessed where the trial was approved (Central ethical committee in Ankara, Turkey). This trial was registered by IRCT with ID as IRCT 2012123010279N2.